Our results are consistent with the long-presumed heightened risk of benign subsequent tumors in this population, which was previously reported only in small case series or individual reports, and likely indicate the involvement of germline RB1 mutations in benign tumor development in these patients. Here, RB1 is linked to benign neoplasm.